Glipizide: A Review of the Pharmacoeconomic Implications of the Extended-Release Formulation in Type 2 Diabetes Mellitus
Year of publication: |
2000
|
---|---|
Authors: | Foster, Rachel H. ; Plosker, Greg L. |
Published in: |
PharmacoEconomics. - Springer Healthcare | Adis, ISSN 1170-7690. - Vol. 18.2000, 3, p. 289-306
|
Publisher: |
Springer Healthcare | Adis |
Subject: | Antihyperglycaemics | Cost analysis | Glipizide | Pharmacoeconomics | Sulphonylureas | Type 2 diabetes mellitus |
Extent: | application/pdf text/html |
---|---|
Type of publication: | Article |
Classification: | C - Mathematical and Quantitative Methods ; D - Microeconomics ; I - Health, Education, and Welfare ; Z - Other Special Topics ; I1 - Health ; I19 - Health. Other ; I18 - Government Policy; Regulation; Public Health ; I11 - Analysis of Health Care Markets |
Source: |
-
Hutubessy, Raymond C.W., (2001)
-
Management of Type 2 Diabetes Mellitus: Defining the Role of Nateglinide
Carswell, Christopher I., (2002)
-
Ramsdell, Joe W., (2003)
- More ...
-
Donepezil: Pharmacoeconomic Implications of Therapy
Foster, Rachel H., (1999)
-
Cefotaxime: A Pharmacoeconomic Review of its Use in the Treatment of Infections
Plosker, Greg L., (1998)
-
Abciximab: A Pharmacoeconomic Review of its Use in Percutaneous Coronary Revascularisation
Dunn, Christopher J., (1999)
- More ...